One Case of Peripheral Neuropathy Induced by Telbivudine Tablets

Abstract

CLC Number:

R994.11

LIU Mengxiao, SONG Jie, ZHANG Chuanhui, JIA Shengnan, SHAO Xue, JIN Zhenjin. One Case of Peripheral Neuropathy Induced by Telbivudine Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 381-382.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2019/V16/I6/381

References

[1] 中华医学会神经病学分会肌电图与临床神经电生理学组,中华医学会神经病学分会神经肌肉病学组.糖尿病周围神经病诊断和治疗共识[J].中华神经科杂志, 2013, 46(11):787-789.
[2] Dispenzieri A.POEMS syndrome: 2014 update on diagnosis,risk-stratification,and management[J]. Am J Hematol,2014,89(2) : 214-223.
[3] Bircan Kayaaslan, Rahmet Guner.Adverse effects of oral antiviral therapy in chronic hepatitis B[J]. World Journal of Hepatology, 2017, 9(5):227-241.
[4] 国家食品药品监督管理局. EMEA警告替比夫定引起周围神经病变的风险[EB/OL].[2008-10-18][2018-08-01].http://www.sda.gov.cr,ⅣS01/CI.,0389/29742.htmL.
[5] 金辉, 周子晔, 王陈翔, 等. 替比夫定引起的严重不良反应分析[J]. 中国现代应用药学, 2018, 35(8):1245-1247.
[6] Fleischer R D,Lok A S.Myopathy and neuropathy associated with nucleos(t) ide analog therapy for hepatitis B[J]. J Hepatol,2009,51(4):787-791.
[7] Pastermask R C, Smith S C, Baireymerz C N, et al.ACC/AHA/NHLB I clinical advisory on the use and safety of statins[J]. Circulation, 2002, 40(3):567-572.
[8] Zhang X S, Jin R, Zhang S B, et al.Clinical features of adverse reactions associated with telbivudine[J]. World J Gastroenterol, 2008, 14(22):3549-3553.
[9] 林巍, 潘陈为, 金玲湘, 等. 替比夫定相关肌病乳酸性酸中毒周围神经病变1例并文献复习[J]. 温州医学院学报, 2012, 42(1):89-90.
[10] 杜宁, 胡瑾华, 王慧芬. 替比夫定导致周围神经病变3例报道[J]. 传染病信息, 2009, 22(4):254-255.
[11] 姚勤伟, 郭雁宾. 替比夫定联合干扰素α治疗慢性乙型肝炎致周围神经病变4例[J]. 中国新药与临床杂志, 2009, 28(5):399-400.
[12] 国家食品药品监督管理局. 诺华制药称替比夫定与干扰素同时使用可导致周围神经病变[EB/OL]. (2008-10-18)[2018-09-01]. http://www.sda.gov.cn/WS01/CL0389/30364.htmL.

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.